Symmetries and reversing symmetries of area-preserving polynomial mappings in generalised standard form

We determine the symmetries and reversing symmetries within G, the group of real planar polynomial automorphisms, of area-preserving nonlinear polynomial maps L in generalised standard form, L: x'=x+p(y), y'=y+q(x'), where p and q are polynomials. We do this by using the amalgamated free product structure of G. Our results lead to normal forms for polynomial maps in generalised standard form and to a classification of the group structures of the reversing symmetry groups for such maps.Comment: 22 page

A family of integrable maps associated with the Volterra lattice

Recently Gubbiotti, Joshi, Tran and Viallet classified birational maps in four dimensions admitting two invariants (first integrals) with a particular degree structure, by considering recurrences of fourth order with a certain symmetry. The last three of the maps so obtained were shown to be Liouville integrable, in the sense of admitting a non-degenerate Poisson bracket with two first integrals in involution. Here we show how the first of these three Liouville integrable maps corresponds to genus 2 solutions of the infinite Volterra lattice, being the g = 2 case of a family of maps associated with the Stieltjes continued fraction expansion of a certain function on a hyperelliptic curve of genus g ⩾ 1. The continued fraction method provides explicit Hankel determinant formulae for tau functions of the solutions, together with an algebro-geometric description via a Lax representation for each member of the family, associating it with an algebraic completely integrable system. In particular, in the elliptic case (g = 1), as a byproduct we obtain Hankel determinant expressions for the solutions of the Somos-5 recurrence, but different to those previously derived by Chang, Hu and Xin. By applying contraction to the Stieltjes fraction, we recover integrable maps associated with Jacobi continued fractions on hyperelliptic curves, that one of us considered previously, as well as the Miura-type transformation between the Volterra and Toda lattices

Integrable maps in 4D and modified Volterra lattices

In recent work, we presented the construction of a family of difference equations associated with the Stieltjes continued fraction expansion of a certain function on a hyperelliptic curve of genus g. As well as proving that each such discrete system is an integrable map in the Liouville sense, we also showed it to be an algebraic completely integrable system. In the discrete setting, the latter means that the generic level set of the invariants is an affine part of an abelian variety, in this case the Jacobian of the hyperelliptic curve, and each iteration of the map corresponds to a translation by a fixed vector on the Jacobian. In addition, we demonstrated that, by combining the discrete integrable dynamics with the flow of one of the commuting Hamiltonian vector fields, these maps provide genus g algebro-geometric solutions of the infinite Volterra lattice, which justified naming them Volterra maps, denoted V_g. The original motivation behind our work was the fact that, in the particular case g=2, we could recover an example of an integrable symplectic map in four dimensions found by Gubbiotti, Joshi, Tran and Viallet, who classified birational maps in 4D admitting two invariants (first integrals) with a particular degree structure, by considering recurrences of fourth order with a certain symmetry. Hence, in this particular case, the map V_2 yields genus two solutions of the Volterra lattice. The purpose of this note is to point out how two of the other 4D integrable maps obtained in the classification of Gubbiotti et al. correspond to genus two solutions of two different forms of the modified Volterra lattice, being related via a Miura-type transformation to the g=2 Volterra map V_2. We dedicate this work to a dear friend and colleague, Decio Levi

A Model for the Development of the Rhizobial and Arbuscular Mycorrhizal Symbioses in Legumes and Its Use to Understand the Roles of Ethylene in the Establishment of these two Symbioses

We propose a model depicting the development of nodulation and arbuscular mycorrhizae. Both processes are dissected into many steps, using Pisum sativum L. nodulation mutants as a guideline. For nodulation, we distinguish two main developmental programs, one epidermal and one cortical. Whereas Nod factors alone affect the cortical program, bacteria are required to trigger the epidermal events. We propose that the two programs of the rhizobial symbiosis evolved separately and that, over time, they came to function together. The distinction between these two programs does not exist for arbuscular mycorrhizae development despite events occurring in both root tissues. Mutations that affect both symbioses are restricted to the epidermal program. We propose here sites of action and potential roles for ethylene during the formation of the two symbioses with a specific hypothesis for nodule organogenesis. Assuming the epidermis does not make ethylene, the microsymbionts probably first encounter a regulatory level of ethylene at the epidermis–outermost cortical cell layer interface. Depending on the hormone concentrations there, infection will either progress or be blocked. In the former case, ethylene affects the cortex cytoskeleton, allowing reorganization that facilitates infection; in the latter case, ethylene acts on several enzymes that interfere with infection thread growth, causing it to abort. Throughout this review, the difficulty of generalizing the roles of ethylene is emphasized and numerous examples are given to demonstrate the diversity that exists in plants

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting

This manuscript provides nomenclature recommendations developed by an international workgroup to increase transparency and standardization of pharmacogenetic (PGx) result reporting. Presently, sequence variants identified by PGx tests are described using different nomenclature systems. In addition, PGx analysis may detect different sets of variants for each gene, which can affect interpretation of results. This practice has caused confusion and may thereby impede the adoption of clinical PGx testing. Standardization is critical to move PGx forward

Pulmonary, Gonadal, and Central Nervous System Status after Bone Marrow Transplantation for Sickle Cell Disease

We conducted a prospective, multicenter investigation of human-leukocyte antigen (HLA) identical sibling bone marrow transplantation (BMT) in children with severe sickle cell disease (SCD) between 1991 and 2000. To determine if children were protected from complications of SCD after successful BMT, we extended our initial study of BMT for SCD to conduct assessments of the central nervous system (CNS) and of pulmonary function 2 or more years after transplantation. In addition, the impact on gonadal function was studied. After BMT, patients with stroke who had stable engraftment of donor cells experienced no subsequent stroke events after BMT, and brain magnetic resonance imaging (MRI) exams demonstrated stable or improved appearance. However, 2 patients with graft rejection had a second stroke after BMT. After transplantation, most patients also had unchanged or improved pulmonary function. Among the 11 patients who had restrictive lung changes at baseline, 5 were improved and 6 had persistent restrictive disease after BMT. Of the 2 patients who had obstructive changes at baseline, 1 improved and 1 had worsened obstructive disease after BMT. There was, however, significant gonadal toxicity after BMT, particularly among female recipients. In summary, individuals who had stable donor engraftment did not experience sickle-related complications after BMT, and were protected from progressive CNS and pulmonary disease

RANTES/CCL5 and risk for coronary events: Results from the MONICA/KORA Augsburg case-cohort, Athero-express and CARDIoGRAM studies

Background: The chemokine RANTES (regulated on activation, normal T-cell expressed and secreted)/CCL5 is involved in the pathogenesis of cardiovascular disease in mice, whereas less is known in humans. We hypothesised that its relevance for atherosclerosis should be reflected by associations between CCL5 gene variants, RANTES serum concentrations and protein levels in atherosclerotic plaques and risk for coronary events. Methods and Findings: We conducted a case-cohort study within the population-based MONICA/KORA Augsburg studies. Baseline RANTES serum levels were measured in 363 individuals with incident coronary events and 1,908 non-cases (mean follow-up: 10.2±

Measurement of the mass difference between top quark and antiquark in pp collisions at root s=8 TeV

Peer reviewe

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362